news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Yesterday, Kanghui Pharmaceutical's stock price surged on the basis of the daily limit on the 9th, with a transaction volume of 187 million yuan, a surge of 7.74%.However, today it was a reversal of the previous trend, with the stock hitting the limit down during trading. As of press time, the latest price was 13.41 yuan per share, with a transaction volume of 28.61 million yuan.

Regarding the stock price limit down,A reporter from Southern Finance and Economics Omnimedia contacted Kanghui Pharmaceutical's investor relations department as an investor, and the relevant person said, "We are not very clear about it either, (stock price fluctuations) are all market behaviors."

Recently, many investors have speculated that Hengchang Pharmaceutical, which has just been delisted, may go public by using Kanghui Pharmaceutical's "shell".

Recently, Kanghui Pharmaceutical announced that its shareholder TBP Traditional Medicine Investment Holdings (HK) Limited (hereinafter referred to as "TBP") will transfer part of its shares in the company to Shanghai Celexan Enterprise Management Consulting Co., Ltd. (hereinafter referred to as "Celexan"). Before this equity change, TBP held 14.81% of the company's shares and Celexan did not hold any shares. After this equity change, TBP holds 4.81% of the company's shares and Celexan holds 10% of the company's shares. If the transfer is completed, Celexan will become the second largest shareholder of Kanghui Pharmaceutical. It is worth noting that Hunan Hengchang Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Hengchang Pharmaceutical"), which has just terminated its IPO, is Celexan's controlling shareholder. Image source: Tianyancha

In this regard, Kanghui PharmaceuticalThe person said, "We don't know about the situations you mentioned. If there is any relevant situation, we will announce it as soon as possible."

At present, whether Saixianle has entered the company's board of directors and management,The above-mentioned person said,"No, the equity it (Saixianle) bought from the second largest shareholder needs to be transferred through an agreement. The formalities are being processed now and have not been completed yet. If the equity transfer procedures are completed later, Saixianle will be a shareholder holding 10% of the shares. According to the Company Law, it enjoys certain rights and obligations."

As of the end of the first quarter of 2024, Kanghui Pharmaceutical's largest shareholder is Shaanxi Kanghui Holding Co., Ltd. (holding 36.75% of the shares), and the actual controller is Wang Yanling.

(Disclaimer: The content of this article is for reference only and does not constitute investment advice. Investors act accordingly at their own risk.)